RxDoctor Payments Data

Karen Raben, MD

Family Medicine · Miami, FLNPI 1184602203

Payments from drug & device makers

$12,892in general payments, 2019–2025

Across 572 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$4K
  • Gilead$2K
  • Johnson & Johnson$1K
  • AstraZeneca$874
  • AbbVie$750
  • GSK$609
  • plus $3K from 33 others

What the payments were for

  • Consulting fees$3503%
  • Food & beverage$12,16694%
  • Education$3763%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,892 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$90,414
Medicare patients
186
Services billed
1,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala93$438,768
JulucaDolutegravir/Rilpivirine50$184,709
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf27$153,603
TivicayDolutegravir Sodium15$63,550
GenvoyaElviteg/Cob/Emtri/Tenof Alafen15$59,129
PrezcobixDarunavir/Cobicistat22$53,879
IsentressRaltegravir Potassium25$50,101
TriumeqAbacavir/Dolutegravir/Lamivudi11$41,434
EdurantRilpivirine Hcl21$32,659
DescovyEmtricitabine/Tenofov Alafenam12$24,419
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df20$18,323
XareltoRivaroxaban12$6,644
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,310
Testosterone25$3,203
Nebivolol Hcl34$2,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,884$522,316120 claims
Viiv Healthcare CompanyJuluca, Tivicay, Triumeq$4,270$289,69376 claims
Janssen Products, LPSymtuza$414$153,60327 claims
Johnson & JohnsonPrezcobix, Xarelto$1,455$60,52334 claims
MerckIsentress$585$50,10125 claims
GSKAnoro Ellipta$609$5,31012 claims
AbbVieSynthroid$750$1,15411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →